Surrozen, Inc.
SRZN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001824893
In the last 90 days, Surrozen, Inc. insiders filed 0 open-market purchases and 1 sale; 70 institutions reported holding it in 13F filings for Q2 2026, worth $314.5M in total; no superinvestor holds it.
13F holders, Q3 2022
Institutional positions in Surrozen, Inc. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 27
- +3 vs. Q2 2022
- Shares held
- 21.8M
- +717.5K (+3.4%) vs. Q2 2022
- Total value
- $44.1M
- −$19.1M (−30.2%) vs. Q2 2022
- New holders
- 4
- 3 more added
- Sold out
- 1
- 3 more reduced
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting SRZN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 70 | $314.5M |
| Q1 2026 | 59 | $314.2M |
| Q4 2025 | 55 | $195.1M |
| Q3 2025 | 36 | $81.7M |
| Q2 2025 | 31 | $53.9M |
| Q1 2025 | 30 | $63.5M |
| Q4 2024 | 24 | $35.4M |
| Q3 2024 | 23 | $25.5M |
| Q2 2024 | 21 | $23.1M |
| Q1 2024 | 16 | $15.0M |
| Q4 2023 | 17 | $9.78M |
| Q3 2023 | 25 | $7.90M |
| Q2 2023 | 22 | $8.62M |
| Q1 2023 | 23 | $9.91M |
| Q4 2022 | 26 | $9.36M |
| Q3 2022 | 27 | $44.1M |
| Q2 2022 | 24 | $63.1M |
| Q1 2022 | 30 | $67.4M |
| Q4 2021 | 32 | $153.5M |
| Q3 2021 | 29 | $150.7M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Surrozen, Inc.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Wells Fargo & Company | 142 | $0 | 0.00% | −4−2.7% | Reduced |
| JPMorgan Chase & Co | 3 | $0 | 0.00% | +3 | New |
| Tower Research Capital LLC (TRC) | 572 | $1.00K | 0.00% | +572 | New |
| UBS Group AG | 787 | $2.00K | 0.00% | +787 | New |
| Morgan Stanley | 5,017 | $10.0K | 0.00% | +5,017 | New |
| Perceptive Advisors LLC | 6,017 | $12.0K | 0.00% | 00.0% | Unchanged |
| Wolverine Asset Management LLC | 8,725 | $17.0K | 0.00% | +364+4.4% | Added |
| Northern Trust Corp | 35,833 | $72.0K | 0.00% | 00.0% | Unchanged |
| Jasper Ridge Partners, L.P. | 46,838 | $95.0K | 0.01% | 00.0% | Unchanged |
| State Street Corp | 70,932 | $143.0K | 0.00% | 00.0% | Unchanged |
| Prelude Capital Management, LLC | 73,843 | $149.0K | 0.01% | 00.0% | Unchanged |
| BlackRock Inc. | 84,628 | $171.0K | 0.00% | −14,500−14.6% | Reduced |
| Geode Capital Management, LLC | 172,370 | $348.0K | 0.00% | 00.0% | Unchanged |
| Hudson Bay Capital Management LP | 195,400 | $395.0K | 0.00% | 00.0% | Unchanged |
| Empery Asset Management, LP | 215,942 | $436.0K | 2.59% | −41,824−16.2% | Reduced |
| FMR LLC | 252,900 | $511.0K | 0.00% | 00.0% | Unchanged |
| Samsara BioCapital, LLC | 300,000 | $606.0K | 0.14% | 00.0% | Unchanged |
| Alyeska Investment Group, L.P. | 305,648 | $617.0K | 0.01% | 00.0% | Unchanged |
| Vanguard Group Inc | 487,278 | $984.0K | 0.00% | +15,299+3.2% | Added |
| Bridger Management, LLC | 700,001 | $1.41M | 0.43% | 00.0% | Unchanged |
| Board of Trustees of The Leland Stanford Junior University | 781,960 | $1.58M | 0.10% | +757,546+3,102.9% | Added |
| Euclidean Capital LLC | 802,963 | $1.62M | 1.51% | 00.0% | Unchanged |
| Harvard Management Co Inc | 826,852 | $1.67M | 0.21% | 00.0% | Unchanged |
| HHLR Advisors, Ltd.SuperinvestorHHLR Advisors (Hillhouse) | 1,200,000 | $2.42M | 0.06% | 00.0% | Unchanged |
| Baker Bros. Advisors LP | 2,500,000 | $5.05M | 0.03% | 00.0% | Unchanged |
| Consonance Capital Management LP | 3,497,500 | $7.07M | 97.05% | 00.0% | Unchanged |
| The Column Group LLC | 9,248,129 | $18.7M | 4.13% | 00.0% | Unchanged |
| Penserra Capital Management LLC | 0 | $0 | 0.00% | −5,722−100.0% | Sold out |